AI-generated research brief — verify at source
4CMenB Vaccine Shows No Efficacy Against Gonorrhoea in MSM Trial
A double-blind, placebo-controlled randomised trial found no statistically significant reduction in gonorrhoea incidence among men who have sex with men (MSM) receiving the 4CMenB meningococcal B vaccine compared to placebo, with a hazard ratio suggesting no meaningful protective effect (HR 0.76, 95% CI 0.31–1.87). The wide confidence interval means a modest benefit cannot be formally excluded, but the result is broadly neutral and does not support vaccine efficacy in this population.
What Was Studied
The trial investigated whether the 4CMenB vaccine — a meningococcal group B vaccine with outer membrane vesicle components that share antigenic similarity with Neisseria gonorrhoeae — could reduce the incidence of gonorrhoea infection among MSM, a population disproportionately affected by antimicrobial-resistant gonorrhoea. The primary outcome was the occurrence of a first gonorrhoea episode within the first year of follow-up.
How It Was Studied
This was a prospective, double-blind, randomised placebo-controlled trial (registered as NCT05766904) conducted in Hong Kong between 2023 and 2024. A total of 152 MSM aged 18 to 50 years were enrolled and randomly assigned in a 1:1 ratio to either the 4CMenB vaccine or placebo, using permuted blocks of four to ensure balanced allocation. Participants received two injections administered at least one month apart and attended scheduled follow-up visits every three months for a total of two years. Gonorrhoea incidence during the first year constituted the primary analysis window, with ongoing follow-up extending into the second year.
What Was Observed
- Gonorrhoea incidence rates were similar between the two arms, with the vaccine arm showing no meaningful reduction compared to controls — a roughly 24% lower risk that was statistically indistinguishable from chance (HR 0.76, 95% CI 0.31–1.87). The control arm incidence was 0.78 episodes per person-year (95% CI 0.64–0.95) and the vaccine arm was 0.86 (95% CI 0.77–0.96), with the vaccine arm numerically slightly higher.
- Vaccine recipients were significantly more likely to report reduced worry about acquiring gonorrhoea after receiving the vaccine — approximately twice the odds compared to the control arm (adjusted OR 2.10, 95% CI 1.22–3.59). This shift in risk perception was statistically robust and was accompanied by a lower rate of condom use following unblinding in the vaccine arm.
- Adverse effects were more commonly reported among participants who received the 4CMenB vaccine compared to those who received placebo, consistent with the known reactogenicity profile of this vaccine.
Why This Matters
The findings challenge the hypothesis that cross-reactive immune responses induced by 4CMenB vaccination translate into clinically meaningful protection against gonorrhoea in high-risk MSM populations, at least under the conditions of this trial. Beyond efficacy, the observation that vaccination was associated with reduced risk perception and lower condom use after unblinding raises an important concern: even a vaccine perceived as potentially protective may prompt behavioural changes that increase net exposure to sexually transmitted infections. This risk compensation dynamic has direct implications for how future STI vaccine trials are designed and how public health messaging around such vaccines should be framed.
How to Read This Result
Given the small sample size and the resulting imprecision in the primary efficacy estimate — reflected in confidence intervals spanning from a substantial potential benefit to a meaningful potential harm (HR 0.76, 95% CI 0.31–1.87) — this trial was insufficiently powered to definitively rule out a modest protective effect, and its findings should be interpreted as inconclusive rather than as definitive evidence of no benefit.
Limitations
The most consequential limitation is the small sample size of 152 participants, which substantially reduces statistical power and yields wide confidence intervals that prevent firm conclusions about efficacy. The behavioural risk compensation observed after unblinding — specifically reduced condom use in the vaccine arm — may have obscured any underlying biological protection by increasing exposure risk. Although participants were followed for two years, the primary efficacy outcome was assessed only over the first year, leaving longer-term dynamics unexplored. Additionally, this was a single-city study conducted in Hong Kong, which may restrict the generalisability of findings to MSM populations in other geographic or epidemiological settings.